You are here

  • Home
  • Archive
  • Volume 75, Issue 7
  • Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs

Article info

Article menu

This article has a correction. Please see:

Clinical and epidemiological research
Extended report
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs

Authors

  1. Correspondence to Dr Eustratios Bananis, US Medical Affairs, Inflammation & Immunology, Global Innovative Pharma, Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA; stratis.bananis{at}pfizer.com
View Full Text

Citation

Charles-Schoeman C, Burmester G, Nash P, et al
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
Annals of the Rheumatic Diseases 2016;75:1293-1301.

Publication history

  • Received December 18, 2014
  • Revised June 24, 2015
  • Accepted July 14, 2015
  • First published August 14, 2015.
Online issue publication 
October 31, 2019

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Lay summary

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/